Agenus/LinkedIn
May 2, 2025, 16:17
Myriam Chalabi Discusses Neoadjuvant Immunotherapy and NEOASIS Study Findings at AACR25 – Agenus
Agenus shared a post on LinkedIn:
“Yesterday at AACR25, Dr. Myriam Chalabi participated in the session ‘Neoadjuvant Treatment Across Tumor Types: One Size Does Not Fit All,’ where she discussed the evolving neoadjuvant landscape and the promising role of immunotherapy—including clinical studies evaluating botensilimab and balstilimab.
Learn more and view her NEOASIS study presentation.”
More posts featuring AACR25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 2, 2025, 15:24
May 2, 2025, 14:52
May 2, 2025, 14:44
May 2, 2025, 14:40
May 2, 2025, 14:32